Pular para o conteúdo principal
Ranking Invest

KALV - KalVista Pharmaceuticals, Inc.

Segmento: HealthcareKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Dados da Empresa

Patrimônio Líquido

$ 95.39 Mi

Dívida Líquida

-$ 92.34 Mi

L4T

-$ 183.44 Mi

Indicadores Básicos

ROE

-192.31%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.18

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

G-10.33

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.97

DIV/L4T

0.50

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.